LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Capillary and Venous Lactate Compared in ED Patients

By LabMedica International staff writers
Posted on 16 Apr 2019
Image: The Automatic QC RAPID Systems RAPIDPoint 500 blood gas analyzer (Photo courtesy of Siemens Healthcare).
Image: The Automatic QC RAPID Systems RAPIDPoint 500 blood gas analyzer (Photo courtesy of Siemens Healthcare).
Elevated lactate levels are a common finding in acutely unwell patients. Blood lactate level is a good predictor of patient outcome and high lactate levels are associated with high morbidity and mortality. Lactate may be detected and measured in all blood samples: arterial, venous and capillary.

Currently, blood lactate can be measured formally in the laboratory, using blood gas analyzers or with handheld devices. Strong correlations have been shown between blood lactate levels in samples analyzed in the central laboratory, by blood gas analyzers and handheld devices. Capillary blood lactate testing with handheld analyzers has great advantages to reduce the time needed for clinical decisions, and for extended use in the prehospital setting.

Emergency department (ED) personnel at the Chinese University of Hong Kong (Shatin, Hong Kong) and their colleagues carried out a prospective observational study of patients presenting to the ED of Prince of Wales Hospital (Shatin, Hong Kong) and 240 patients (mean age 69.9 years) were recruited. Venous and capillary blood samples were collected for lactate analysis. Venous blood samples (approximate 1 mL) were collected by venipuncture while capillary blood samples were collected by finger-prick with a disposable lancet.

Venous lactate levels were measured by blood gas analyzer the Siemens Automatic QC RAPID Systems RAPIDPoint 500 (VL-Ref) served as the reference standard. Capillary lactate levels were immediately analyzed by two handheld lactate analyzers: Nova StatStrip Xpress Lactate Meter (CL-Nova) and Lactate Scout+ (CL-Scout). Venous lactate levels were also measured on the two handheld lactate analyzers. All lactate measurements were performed within 15 minutes after obtaining the venous sample.

The scientists reported that the results of VL-Ref ranged from 0.70 to 5.38 mmol/L (mean of 1.96 mmol/L). Regarding capillary lactate measurements, the bias (mean difference) between VL-Ref and CL-Scout+ was −0.22 with 95% limits of agreement (LOA) of −2.17 to 1.73 mmol/L and the bias between VL-Ref and CL-Nova was 0.46, with LOA of −1.08 to 2.00 mmol/L. For venous lactate, results showed the bias between VL-Ref and VL-Scout+ were 0.22 with LOA being −0.46 to 0.90 mmol/L, and the bias between VL-Ref and VL-Nova was 0.83 mmol/L with LOA −0.01 to 1.66 mmol/L.

The author concluded that their study shows poor agreement between capillary lactate and reference values. The study does not support the clinical utility of capillary lactate point-of-care testing (POCT). However, venous lactate measured by Scout+ handheld analyzer may have potential for screening patients who may need further testing. The study was published on April 3, 2019, in the journal BMJ OPEN.

Related Links:
Chinese University of Hong Kong
Prince of Wales Hospital

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more